Ladenburg Thalmann Reiterates Buy on TG Therapeutics, Maintains $39 Price Target
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Matthew Kaplan has reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) and maintained a $39 price target.
April 18, 2024 | 5:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ladenburg Thalmann analyst Matthew Kaplan reiterates a Buy rating on TG Therapeutics with a $39 price target.
The reiteration of a Buy rating and maintenance of a $39 price target by a reputable analyst suggests a strong vote of confidence in TG Therapeutics. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in TGTX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100